The de-SPAC merger surge continued during the first half of the year, with the number of tech and life sciences companies going public via SPAC merger increasing 71 percent from the second half of 2020, Fenwick reports in JD Supra.
Additionally, the four direct listings in H1 2021 were double the number in the previous half year. Read more.
